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Abstract. 
One of the current strategies to prevent malaria in pregnancy is intermittent preventive treatment with 
sulfadoxine-pyrimethamine (IPTp-SP). However, in order for pregnant women to receive an adequate number of 
SP doses, they should attend a health facility on a regular basis. In addition, SP resistance may decrease IPTp-
SP efficacy. New or additional interventions for preventing malaria during pregnancy are therefore warranted. 
Because it is known that community health workers (CHWs) can diagnose and treat malaria in children, in this 
study screening and treatment of malaria in pregnancy by CHWs was evaluated as an addition to the regular 
IPTp-SP program. CHWs used rapid diagnostic tests (RDTs) for screening and artemether–lumefantrine was 
given in case of a positive RDT. Overall, CHWs were able to conduct RDTs with a sensitivity of 81.5% (95% 
confidence interval [CI] 67.9–90.2) and high specificity of 92.1% (95% CI 89.9–93.9) compared with 
microscopy. After a positive RDT, 79.1% of women received artemether–lumefantrine. When treatment was not 
given, this was largely due to the woman being already under treatment. Almost all treated women finished the 
full course of artemether–lumefantrine (96.4%). In conclusion, CHWs are capable of performing RDTs with 
high specificity and acceptable sensitivity, the latter being dependent on the limit of detection of RDTs. 
Furthermore, CHWs showed excellent adherence to test results and treatment guidelines, suggesting they can be 
deployed for screen and treat approaches of malaria in pregnancy. 
BACKGROUND 
Malaria in pregnancy can cause several adverse outcomes such as maternal anemia, 
stillbirths, miscarriage, and low birth weight (reviewed by Desai and others).1 The current 
key strategy for prevention of malaria in pregnancy is intermittent preventive treatment with 
sulfadoxine–pyrimethamine (IPTp-SP). IPTp-SP consists in the administration of SP during 
the second and third trimester when the women attend the antenatal care clinic (ANC),2 and 
has proven effective in preventing placental malaria and low birth weight.3 The World Health 
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Organization (WHO) recommends that SP is administered at each antenatal care visit in the 
second and third trimester, provided it is at least a month apart from the previous dose.2 
However, IPTp-SP coverage of at least two doses is low in many sub-Sahara African 
countries (on average 21.5%).4 Reasons for low coverage are a lack of coordination and 
leadership, financial constraints, unmotivated and unsupported health staff, perceived risk of 
the medication, logistic challenges, and ANC attendance among others.5–7 Adolescents and 
primigravidae, who have among pregnant women the highest risk of malaria, are even less 
likely to receive sufficient doses of IPTp-SP, mainly due to low ANC attendance.6 Besides 
the unsatisfactory uptake of IPTp-SP, SP resistance is widespread and rising in most sub-
Saharan African countries.8–10 In east Africa, where resistance is the highest of sub-Saharan 
Africa,11 the efficacy of IPTp-SP seems already compromised.12–15 Therefore, it is important 
to explore alternative or additional preventive measures. 
Community case management of malaria (CCMm) aims at reducing malaria morbidity in 
children, by improving the access to diagnosis and treatment of malaria. CCMm relies on 
members of community, often named community health workers (CHW), who have been 
trained in diagnosing malaria with rapid diagnostic tests (RDTs) and administering an 
antimalarial treatment to positive tested children.16 The strategy is effective as CHWs are 
capable of performing RDTs with a fair sensitivity (generally more than 85% compared with 
microscopy).17 Because of these positive results, an intervention based on this strategy was 
considered for pregnant women. In this intervention, CHWs were mobilized to screen 
pregnant women for malaria with RDTs at monthly intervals, between antenatal care visits.18 
Besides increasing the chance of detecting and treating malaria infections, this strategy also 
increases the total number of health-care contacts during pregnancy, something that is 
strongly encouraged by the WHO.19 The performance of RDTs used by CHWs on pregnant 
women in rural Burkina Faso is reported here, including the adherence of CHWs and 
pregnant women to the test results and to treatment guidelines. 
METHODS 
This study was nested in a cluster-randomized controlled trial (COSMIC; Trial 
Registration: Current Controlled Trials ISRCTN37259296 and clinicaltrials.gov 
NCT01941564) carried out in Benin, The Gambia, and Burkina Faso, as described 
previously.18 The aim of the main trial was to assess the efficacy of community screening and 
treatment of malaria during pregnancy on placental malaria. Here, the quality of RDT use by 
CHWs in pregnant women and adherence to treatment guidelines is described for the Burkina 
Faso study site. 
Study procedures. 
The intervention of community screening and treatment of malaria during pregnancy was 
conducted in 15 villages in the Nanoro health-center catchment area, about 85 km northwest 
of Ouagadougou. Malaria is endemic in this region, but has a seasonal pattern with peak 
transmission occurring toward the end of the rainy season (that lasts from June until 
October). CHWs were instructed to pay monthly visits to pregnant women in their second 
and third trimester up to delivery. In each village there was a single CHW participating in the 
study, except for one village in which the initial CHW got a new job outside the study area 
and was therefore replaced. At each home visit, CHWs performed a RDT (SD Bioline Ag-
Pf), irrespective of symptoms, and if positive administered artemether–lumefantrine 
(COARTEM®). Treatment was not given if a woman reported to have received a course of 
artemether–lumefantrine in the past 3 weeks. Seriously ill women were referred to the health 
center. RDT results and any given treatment were recorded on a CRF by the CHW 
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(Supplemental Material 1). In addition, the CHW collected a blood slide and blood spots on 
filter paper. All treated women were visited after 3 days by the CHW, to assess treatment 
adherence by administering a questionnaire and by checking the empty blisters. The number 
of tablets remaining and reasons for nonadherence were recorded in another CRF 
(Supplemental Material 2). Besides the home visits, pregnant women were encouraged by the 
CHWs to visit the ANC. At each ANC visit the woman received standard care, including 
IPTp-SP. Furthermore, a blood slide and filter paper were collected and clinical data and any 
given treatment was recorded on a CRF (Supplemental Materials 3 and 4). 
Study population and sample size. 
All women resident in the study area and without a known sensitivity to sulphonamides 
were eligible for inclusion in the COSMIC study. Pregnant women enrolled in intervention 
villages (N = 900) in Burkina Faso were included in the analyses of the current study.18 
Community health workers. 
CHWs included in the study were already involved in community sensitization and 
organization of vaccination and malnutrition campaigns. Each of the CHWs was linked to a 
health facility. CHWs followed a program before the beginning of the trial in which they 
were trained in malaria symptoms and recognition of danger signs, the use of RDTs and the 
need and purpose of screening pregnant women for malaria. They were also explained the 
benefits of IPTp–SP and advised to promote ANC visits and SP uptake among the pregnant 
women. CHWs were supervised by field workers. 
Rapid diagnostic tests. 
RDTs used by the CHWs targeted the Plasmodium falciparum histidine-rich protein 2 
(HRP2) antigen. A central stock of RDTs was kept at the Unité de Recherche Clinique de 
Nanoro (URCN) and the CHWs were supplied with small stocks at a regular basis. In case of 
an invalid test result, CHWs were instructed to repeat the RDT. 
Microscopy. 
Filter papers and blood slides collected at home visits in intervention villages were 
transferred to the laboratory (URCN) on the same day. Blood slides were stained with 
Giemsa 3% for 45–60 minutes. Slides were read by two independent expert microscopists 
blinded to the RDT results. The number of parasites were counted against 200 leukocytes, or 
against 500 leukocytes if the count was < 10 parasites/200 leukocytes. Slides were considered 
negative if no parasites were seen after examination of 100 high power fields. Any 
discrepancies between the two readings were resolved by consulting a third independent 
blinded reader. 
Real-time Polymerase chain reaction. 
Filter papers were air dried, sealed in bags with silica, and stored at room temperature 
until shipment to the Netherlands (Academic Medical Center, Amsterdam). For each selected 
filter paper, a blood spot was punched out using Acu-Punch skin biopsy punchers (acuderm® 
inc, FL) and transferred to a 5-mL polystyrene tube with lysis buffer (bioMérieux, Marcy-
l’Étoile, France). The tubes were placed on a roller bank for 30 minutes. After lysis, the fluid 
was transferred to easyMag vessels and Magnetic Bead Silica were added. DNA was 
extracted using the NucliSENS easyMag DBS 1.0 protocol (bioMérieux, Marcy-l’Étoile, 
France). Positive and negative controls were included (blood spots from 
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ethylenediaminetetraacetic acid (EDTA) blood spiked with 3D7 or FCR3 culture and blood 
spots of uninfected EDTA blood of the Dutch blood bank). Samples were stored at 20°C. 
Real-time polymerase chain reaction (PCR) for detection of P. falciparum DNA was 
performed as previously described with minor modifications.20,21 In each reaction 2.5 L of 
DNA, 5 mM MgCl2, 2.5 L of 10  PCR Buffer, 0.125 L of HotStarTaq DNA Polymerase, 
0.25 mM of each dNTP, 0.4 M of each primer, and 0.1 µM of FAM-labeled probe (‘5-
aacaattggagggcaagg-3) were used. PCR Mix reagents were ordered from Qiagen (Hilden, 
Germany) and all primers from Biolegio (Nijmegen, the Netherlands). In each plate, a 
dilution series of P. falciparum FCR3 culture was included (104 parasites/µL–1 parasites/µL) 
as well as positive and negative DNA extraction controls and Milli-Q water. Reactions were 
run on Bio-Rad CFX real-time PCR machine with the following settings: initial denaturation 
95°C for 10 minutes, 40 cycles of 95°C for 60 seconds, and 60°C for 20 seconds. Results 
were analyzed using Bio-Rad CFX manager software (version 3.1). 
Statistical analyses. 
All analyses were done using Stata 14.0. Microscopy was used as the reference test for 
RDT performance. A subanalysis at first home visit was done with real-time PCR as the 
reference test, because it has been shown that submicroscopic infections are also clinically 
important as they can result in maternal anemia and preterm or low birth weight babies.22 
Sensitivity (proportion of correctly identified positive samples), specificity (proportion of 
correctly identified negative samples), positive predictive value (proportion of diseased after 
a positive RDT result; positive predictive value [PPV]), negative predictive values 
(proportion of nondiseased after a negative RDT result; negative predictive value NPV), and 
prevalence (proportion of positive test results of all tests performed) were calculated by using 
logistic regression with robust standard errors to take clustering of tests within CHWs into 
account. For sensitivity and specificity analysis stratified by CHW, logistic regression with 
robust standard errors was used to account for repeated measurements of participants. 
However, for CHWs with 100% RDT sensitivity exact binomial confidence intervals were 
calculated since no between-woman variation was observed. For comparisons of parasite 
density, Mann–Whitney U tests were performed for skewed data distributions. 
Ethics. 
Informed consent was obtained for each participating community prior to the start of the 
trial. During the study, informed consent was obtained for each participating woman. The 
study protocol was reviewed and ethically approved by the Institutional Ethics Committee of 
Center Muraz in Burkina Faso on 19 September 2013 (ref A20-2013/CE-CM). 
RESULTS 
Pregnant women were enrolled over a period of 18 months; including follow-up the study 
lasted approximately 2 years in Burkina Faso (March 2014–January 2016). A total of 900 
women were recruited in 15 villages allocated to the intervention arm; of 861 women at least 
one home visit was recorded (Figure 1). The mean age of the women was 26 years old 
(standard deviation 6.3), with 10.5% of the women aged 18 or below; 19.2% (165/861) of 
women were primigravidae and 14.9% (128/861) secundigravidae. The modal number of 
visits per pregnancy was three (40.0%) though some women had up to six visits (Table 1). In 
total, 2,516 home visits were done. There were 2,507 recorded RDT results, with 307 
(12.2%) positive tests; 242 women tested positive at least once (up to a maximum of four 
times) (Figure 1). Of all microscopy slides, 147 of 2443 (6.0%) were positive. Over 
subsequent home visits, the proportion of positive RDTs was consistently higher than that of 
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positive microscopy (P values 0.011; < 0.001; < 0.001; 0.003; and 0.017 for home visits 1–5, 
respectively) (Figure 2). 
RDT versus microscopy. 
Using microscopy as the reference test, RDT sensitivity was 81.5% (95% confidence 
interval [CI] 67.9–90.2) and specificity 92.1% (95% CI 89.9–93.9); PPV was 39.8% (95% CI 
33.0–47.0) and NPV was 98.7% (95% CI 97.6–99.3) (Table 2). When stratified by home visit 
(Table 3), sensitivity ranged between 74.1% and 87.0% without a clear trend over successive 
home visits (P = 0.115). However, specificity decreased over successive home visits (point 
estimates decreased from 96.4 to 87.4%, P < 0.001). Consequently, the PPV differed 
significantly between home visits (P < 0.001); a decrease in PPV was seen over successive 
home visits, except at home visit 4 due to higher malaria prevalence by microscopy. The 
NPV remained high over successive home visits without significant differences (P = 0.086). 
Individual differences between CHWs in RDT sensitivity and specificity are presented in 
Figure 3A and B. Sensitivity ranged from 27.3% up to 100% and specificity from 84.6% to 
98.3%. Variance between CHWs was significant for both sensitivity and specificity with 
intracluster coefficients of 0.37 (P < 0.001) and 0.05 (P < 0.001), respectively. In particular, 
two CHWs (numbers 12 and 14) showed poor sensitivity (50.0%, 95% CI 15.8–84.2 and 
27.3%, 95% CI 8.1–61.4, respectively). Due to the low overall prevalence the NPV remained 
high, 95.6% (95% CI 89.1–98.3) and 93.2% (95% CI 86.3–96.7) for CHW 12 and 14, 
respectively. If the two CHWs were excluded from the analyses, the overall sensitivity 
increased to 88.2% (95% CI 79.8–93.4), whereas the specificity remained similar. 
Discrepancies between RDT and microscopy results were further explored (Tables 4 and 
5). Parasite densities in microscopy positive slides (reference test) were compared between 
positive (true positives) and negative RDTs (false negatives); for the former, the median 
parasite density was 2019.3 parasites/µL (interquartile range [IQR] 703.5–4994.0), whereas it 
was 104 parasites/µL (IQR 72.0–530.5) for the latter (P < 0.001) (Table 4). Almost half of 
the women (48.9%, 88/180) with RDT positive and microscopy negative results (false 
positives) had taken antimalarial treatment (AL, SP, or quinine) within the 2 weeks before the 
RDT testing was performed; this was 62.6% (113/180) when considering the previous 4 
weeks. When including reported but unproven treatment, the proportions increased to 56.1% 
(101/180) and 72.8% (131/180), respectively (Table 5). 
RDT versus real-time PCR. 
From first home visit, 628 RDTs were available for analyses. Malaria prevalence by real-
time PCR was 6.0% (95% CI 4.3–8.1%). When taking real-time PCR as reference test and 
after correction for clustering, RDT sensitivity was 75.7% (95% CI 66.2–83.2) and specificity 
96.6% (95% CI 94.2–98.0) (Table 3). 
Median parasite density (by real-time PCR) was 34.65 parasites/µL (IQR 10.4–111.3) in 
true-positive RDTs and 1.12 parasites/µL (IQR 0.5–20.6) in false-negative RDTs (P = 0.04) 
(Table 6). Of women with a false-positive RDT, 40% (8/20) had used antimalarial treatment 
within the last 4 weeks, when including reported but unproven treatment this increased to 
55% (11/20) (Table 7). 
Adherence to test results by CHWs and pregnant women. 
Of RDT positive women 79.1% (239/302) were treated with artemether–lumefantrine by 
the CHW. The most common reason for not giving treatment despite a positive RDT was 
ongoing treatment (77.9%). Furthermore, in four cases the CHW reported that he/she had no 
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artemether–lumefantrine in stock. For the remaining 11 cases, the reason for nonadherence to 
the treatment protocol is unknown (Table 8). Full adherence to the drug regimen by pregnant 
women was 96.5% (no antimalaria tablets left after 3 days). Reasons for nonadherence were 
side-effects (3/7), the woman forgot to take the medication (1/7) or the woman was already 
under treatment (1/7) (Table 8). 
DISCUSSION 
CHW are able to screen pregnant women for malaria with RDTs and treat them 
adequately if positive. CHWs were able of performing RDTs with a fair sensitivity of 81.5% 
(95% CI 67.9–90.2) and specificity of 92.1% (95% CI 89.9–93.9). Previous studies on HRP2-
based RDTs performed by professional health care showed higher sensitivity (94%, 95% CI 
91–96) on average, but lower specificity (81%, 95% CI 71–88) in pregnant women (reviewed 
in Kattenberg and others).23 These differences can be related to RDT brands used, endemic 
settings, or skills in execution of RDTs. The latter could also be the cause of CHWs not doing 
equally well in terms of RDT sensitivity in this study, with two CHWs (12 and 14) 
performing unsatisfactorily (sensitivities of 50% and 27%, respectively). However, the 
CHWs were supervised at a regular basis during the study and no failures in RDT execution 
were reported by the field supervisors. Therefore, it remains unclear if this was a problem of 
RDT execution, or if there are other reasons. Previous studies have shown that mistakes in 
RDT execution are often related to the volume of blood and buffer used, the timing of 
reading, and/or incorrect interpretation of faint bands or invalid results.17 
False-negative RDT results may be explained by the detection threshold of the test 
(around 200 parasites/µL),24,25 as almost 60% of all false negatives had a lower density. The 
large majority (8/11) of RDT false negatives above the 200 parasites/µL threshold, were 
missed by the two poorer performing CHWs, again suggesting mistakes in the execution of 
the tests. However, even if only well performing CHWs would screen pregnant women for 
malaria, it means that some women with low parasite densities would be left untreated. This 
is unfortunate since it has been shown that infections with low parasite densities are also 
related to maternal anemia, low birth weight, and premature births.22 Furthermore, the 
sensitivity of RDTs was calculated against microscopy of peripheral blood, while both these 
methods (as well as real-time PCR of peripheral blood) may miss placental infections.23 
Therefore, the number of women with a malaria infection but not identified by a RDT is 
likely higher than presented here. 
Most false-positive RDT results can probably be attributed to prolonged antigen 
circulation after clearance of a P. falciparum infection. Although microscopy detects live 
parasites that are usually cleared within a few days after treatment, it has been shown that 
HRP2 antigens can persist in the circulation for at least 4 weeks after treatment in pregnant 
women.20 This explains the decreasing specificity over successive home visits; it reflects the 
increased chance of women having experienced a malaria infection from which HRP2 
antigens are still circulating. In our study, 72.6% of the women had used or reported use of 
antimalarial treatment in the 28 days preceding a false-positive RDT. For the remaining false-
positive results, it could be that reporting antimalarial treatment was not always accurate, 
resulting in a recall bias. It could also be that some false-positive results were actually true 
positives, but missed by microscopy reading. This seems to be the case for some positive 
RDTs at home visit 1 that were tested negative by microscopy but positive by real-time PCR. 
The comparisons of RDT with real-time PCR resulted in a lower sensitivity 75.7% (95% 
CI 66.2–83.2) than with microscopy as reference test. Given that real-time PCR can detect 
even lower parasite densities than microscopy (?20 parasites/mL versus 50–100 parasites/µL, 
respectively), this is to be expected.21,25 Compared with two other studies in Burkina Faso in 
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which pregnant women were tested at antenatal care visits by professional health-care 
workers, the sensitivity was high compared with one (sensitivity 55.8%, 95% CI 50.0–
62.4),26 but low compared with the other (90.9%, 95% CI 87.5, 93.6).27 However, both used a 
different test for comparison (nested PCR and not real-time PCR) which could impact on 
sensitivity; in addition, the latter study used both PCR and microscopy as reference test. The 
observation that parasite densities were significantly lower for false-negative RDT samples 
than for true-positive RDT samples in our study, confirmed the idea that the major bottleneck 
was the detection limit of RDTs. 
The specificity of RDTs compared with real-time PCR was high (96.6%, 95% CI 94.2–
98.0) and fairly similar to specificity found in the two previous studies in Burkina Faso 
(99.3%, 95% CI 98.4–99.7 and 94.1%, 95% CI 89.4, 97.1).26,28 Antigen persistence of a 
cleared infection may again be the cause of the few false-positive RDT results, because in 
contrast to antigen, DNA from dead Plasmodium parasites seems to be rapidly cleared from 
the bloodstream.29 
Adherence to test results by CHWs was excellent, given the fact that almost 80% of the 
women were treated after a positive RDT, and that the most common reason for not giving 
treatment was that the woman was already under treatment or had just finished treatment. 
This shows that CHWs were well trained in treatment guidelines and unlikely to overtreat the 
pregnant women. Good adherence to positive test results was shown in previous studies on 
CHWs.17 Furthermore, the high adherence of pregnant women to the full course of AL shows 
the high trust in the CHWs and the test results, at least within this trial context. 
A limitation of this study was the quality of filter paper samples. Although most CHWs 
seemed sufficiently trained in performing RDTs, the correct preparation of filter papers 
turned out to be more difficult. For most blood spots the amount of blood was less than the 
requested 50 µL for which the extraction and real-time PCR were validated. The lack of 
sufficient blood may have led to wrong estimations of parasite density and to false-negative 
real-time PCR results if the parasite density was already low. However, because specificity 
was high for RDTs compared with real-time PCR as reference test, it is unlikely that the latter 
was an issue. 
Furthermore, it is unclear whether the screen and treat intervention by CHWs would work 
as well if it was implemented in the regular health-care system, as the current results were 
obtained during a trial setting in which stock supply was carefully managed and CHWs were 
in close contact with field supervisors. This is something that should be evaluated after 
implementation. This study has highlighted the qualities and the issues of screening pregnant 
women with relatively simple diagnostics for malaria by CHWs. CHWs can perform RDTs 
with acceptable sensitivity and high specificity and have shown good adherence to treatment 
guidelines. The biggest area for improvement, before implementing this intervention, would 
be thorough examination of correct execution of RDTs by all CHWs. Due to the intrinsic 
limitations of the current RDTs, cases with low parasite densities will nevertheless be missed. 
A new simple diagnostic point-of-care test, that can detect lower parasite densities and that is 
preferably less sensitive to antigen persistence, could therefore further improve overall 
performance. In any case, this study has shown that CHWs can be trained and instructed for 
innovative purposes, which might present new opportunities for other public health issues. 
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FIGURE 1. Flow chart of rapid diagnostic tests (RDTs) performed during home visits in intervention arm 
(COSMIC). 
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FIGURE 2. Plasmodium falciparum positive tests (rapid diagnostic test and microscopy) stratified by home visit 
(% and 95% confidence intervals). 
FIGURE 3. (A) Sensitivity of rapid diagnostic test (RDT) vs. microscopy stratified by community health worker 
(CHW) (% and 95% confidence intervals). (B) Specificity of RDT vs. microscopy stratified by CHW (% and 
95% confidence intervals). 
TABLE 1 
Characteristics of pregnant women with at least one home visit 
Participant characteristics (N = 861) 
Age, mean ± SD (median, IQR) 26 ± 6.3 (26, 21–30) 
Gravidity 
 Primigravidae, % (no.) 19.2 (165) 
 Secundigravidae, % (no.) 14.9 (128) 
 Multigravidae, % (no.) 66.0 (568) 
No. of home visits per woman, % (no.) 
 1 9.3 (80) 
 2 22.8 (196) 
 3 40.0 (344) 
 4 22.9 (197) 
 5 4.6 (40) 
 6 0.5 (4) 
IQR = interquartile range; SD = standard deviation. 
TABLE 2 
RDT performance compared with microscopy; sensitivity, specificity, PPV and NPV 
RDT vs. microscopy (N = 
2,434) 
Microscopy 
positive 
Microscopy 
negative Total 
RDT positive 119 180 299 
RDT negative 27 2,108 2,135 
Total 146 2,288  
Sensitivity % (95% CI) 81.5 (67.9–90.2)   
Specificity % (95% CI) 92.1 (89.9–93.9)   
Positive predictive value % 
(95% CI) 
39.8 (33.0–47.0)   
Negative predictive value % 
(95% CI) 
98.7 (97.6–99.3)   
CI = confidence interval; NPV = positive predictive value; PPV = positive predictive value; RDT = rapid 
diagnostic test. 
TABLE 3 
RDT sensitivity and specificity compared with microscopy and real-time PCR, stratified for home visits 1–4 
 Home visit 1 Home visit 2 Home visit 3 Home visit 4 
P 
value 
RDT vs. microscopy, n 837 759 567 228  
Sensitivity (95% CI) 78.6 (62.6–
88.9) 
87.0 (71.9–
94.6) 
74.1 (48.1–
89.8) 
82.8 (55.3–
94.9) 
0.115 
Specificity (95% CI) 96.4 (94.4–
97.7) 
90.3 (86.9–
92.9) 
91.1 (87.8–
93.6) 
87.4 (80.6–
92.1) 
0.000 
Positive predictive value % 
(95% CI) 
53.2 (39.2–
66.7) 
36.7 (28.0–
46.3) 
29.4 (20.4–
40.3) 
49.0 (34.2–
64.0) 
0.000 
Negative predictive value % 
(95% CI) 
98.8 (97.7–
99.4) 
99.0 (97.9–
99.6) 
98.6 (96.5–
99.5) 
97.2 (91.3–
99.1) 
0.086 
RDT vs. qPCR, n 621 NA NA NA  
Sensitivity (95% CI) 75.7 (66.2– NA NA NA NA 
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83.2) 
Specificity (95% CI) 96.6 (94.2–
98.0) 
NA NA NA NA 
Positive predictive value % 
(95% CI) 
58.3 (42.3–
72.8) 
NA NA NA NA 
Negative predictive value % 
(95% CI) 
98.4 (97.5–
99.0) 
NA NA NA NA 
CI = confidence interval; qPCR = quantitative polymerase chain reaction. Home visits 5 and 6 not presented 
because of small sample sizes (N = 39 and N = 4, respectively). 
TABLE 4 
False-negative RDT results (microscopy as reference test): real-time PCR results and parasite density 
Discrepancy N PCR positive Parasite density* 
16 had parasite density < 200 p/µL 
(59.3%) 
False-negative 
RDT (ref 
microscopy) 
27 
(1.1%) 
2/6 (33.3%) 
Median: 104, IQR: 72–530.5 p/µL 
IQR = interquartile range; PCR = polymerase chain reaction; RDT = rapid diagnostic test. 
* By microscopy. 
TABLE 5 
False positive RDT results (microscopy as reference test): real-time PCR results and recent anti-malarial treatment 
N Discrepancy PCR positive 
(HV1) 
AL treatment IPTp-SP Any treatment 
50 had received AL in last 14 days 
(27.8%) 
49 had received SP in last 14 days 
(27.2%) 
88 had received AL, SP or quinine in last 14 days 
(48.9%) 
False positive 
RDT (ref 
microscopy) 
180 
(7.4%) 
6/24 (25%) 
72 had received AL in last 28 days 
(40.0%) 
113 had received AL, SP or quinine in last 28 days 
(62.8%) 
47 reported being under treatment 
with AL 
101 reported or received AL, SP or quinine in last 14 
days (56.1%) 
64 had received SP in last 28 days 
(35.6%) 
131 reported or received AL, SP or quinine in last 28 
days (72.8%) 
IPTp-SP = sulfadoxine-pyrimethamine; PCR = polymerase chain reaction; RDT = rapid diagnostic test. 
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TABLE 6 
False-negative RDT results (real-time PCR as reference test): microscopy results and parasite density 
Microscopy 
positive N Discrepancy Parasitemia* by qPCR 
All had parasitemia < 200 p/µL False-negative 
RDT (ref real-
time PCR) 
9 
(1.4%) 
2/8 (25%) 
Median: 1.1, IQR: 0.47–20.6 
p/µL 
IQR = interquartile range; qPCR = quantitative polymerase chain reaction; RDT = rapid diagnostic test. 
* By qPCR. 
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TABLE 7 
False positive RDT results (real-time PCR as reference test): microscopy results and recent antimalarial treatment 
N Discrepancy Microscopy 
positive 
AL treatment IPTp-SP Any treatment 
4 had received AL in last 14 days 
(20%) 
4 had received SP in last 14 days 
(20%) 
8 had received AL or SP in last 14 days (40%) 
4 had received AL in last 28 days 
(20%) 
False positive 
RDT (ref real-
time PCR) 
20 (3.2%) 2/20 (10%) 
8 had received AL or SP in last 28 days (40%) 
6 reported being under treatment 
with AL 
4 had received SP in last 28 days 
(20%) 
11 reported or received AL, SP or quinine in last 
14 days (55%) 
IPTp-SP = intermittent preventive treatment with sulfadoxine-pyrimethamine; PCR = polymerase chain reaction; RDT = rapid diagnostic test. 
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TABLE 8 
Adherence to treatment guidelines after a positive RDT by CHWs and pregnant women 
AL course 
completed RDT positive AL given Reasons nonadherence CHW 
Reasons nonadherence full AL 
course 
4/46 no AL available 3/7 medicine made woman feel ill N = 307 239/302 
(79.1%) 53/68 already under treatment 
(77.9%) 
1/7 forgot to take medicine 
195/202 (96.5%) 
1/7 was already under treatment 
with AL 
    2/7 unknown 
CHW = community health worker; RDT = rapid diagnostic test. 
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Figure 1. Flow chart of RDTs performed during home visits in intervention arm (COSMIC)  
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Figure 2. P. falciparum positive tests (RDT and microscopy) stratified by home visit (percentage and 
95% confidence intervals) 
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Figure 3a. Sensitivity of RDT versus microscopy stratified by CHW (% and 95% confidence intervals) 
 
Figure 3b. Specificity of RDT versus microscopy stratified by CHW (% and 95% confidence intervals) 
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